Peripheral artery disease (PAD) has been increasingly prevalent, with more than 200 million people estimated to have PAD worldwide.
1,2 This disease has been associated with substantially higher risks of all-cause and cardiovascular (CV) death
3 and is more common among patients with kidney failure than the general population.
4,5 Patients with PAD who are receiving dialysis are also at higher risk of experiencing major adverse limb events (including amputation and hospitalization for critical limb ischemia [CLI]) and death.
6-9